Trial · NCT01106625
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in HbA1c From Baseline to Week 26 | Placebo | -0.13 | Standard Error 0.075 | Percent | |
| Change in HbA1c From Baseline to Week 26 | Canagliflozin 100 mg | -0.85 | Standard Error 0.075 | Percent | |
| Change in HbA1c From Baseline to Week 26 | Canagliflozin 300 mg | -1.06 | Standard Error 0.076 | Percent | |
| Percentage of Patients With HbA1c <7% at Week 26 | Placebo | 18 | Percentage of patients | ||
| Percentage of Patients With HbA1c <7% at Week 26 | Canagliflozin 100 mg | 43.2 | Percentage of patients | ||
| Percentage of Patients With HbA1c <7% at Week 26 | Canagliflozin 300 mg | 56.6 | Percentage of patients | ||
| Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 | Placebo | 4.11 | Standard Error 3.629 | mg/dL | |
| Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 | Canagliflozin 100 mg | -18.2 | Standard Error 3.629 | mg/dL | |
| Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 | Canagliflozin 300 mg | -30.5 | Standard Error 3.650 | mg/dL | |
| Percent Change in Body Weight From Baseline to Week 26 | Placebo | -0.7 | Standard Error 0.3 | Percent change | |
| Percent Change in Body Weight From Baseline to Week 26 | Canagliflozin 100 mg | -2.1 | Standard Error 0.3 | Percent change | |
| Percent Change in Body Weight From Baseline to Week 26 | Canagliflozin 300 mg | -2.6 | Standard Error 0.3 | Percent change | |
| Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 | Placebo | -2.65 | Standard Error 0.982 | mmHg | |
| Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 | Canagliflozin 100 mg | -4.89 | Standard Error 0.976 | mmHg | |
| Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 | Canagliflozin 300 mg | -4.27 | Standard Error 0.980 | mmHg | |
| Percent Change in Triglycerides From Baseline to Week 26 | Placebo | 11.6 | Standard Error 4.2 | Percent change | |
| Percent Change in Triglycerides From Baseline to Week 26 | Canagliflozin 100 mg | 5.4 | Standard Error 4.2 | Percent change | |
| Percent Change in Triglycerides From Baseline to Week 26 | Canagliflozin 300 mg | 8.5 | Standard Error 4.2 | Percent change | |
| Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 | Placebo | 3.2 | Standard Error 1.3 | Percent change | |
| Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 | Canagliflozin 100 mg | 5.7 | Standard Error 1.3 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01106625/results